

Patient Information	Specimen Information	Client Information
<b>DOB:</b> <b>AGE:</b> Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #:  Collected: Received: Reported:	

**COMMENTS:**      FASTING: YES

Test Name	In Range	Out Of Range	Reference Range	Lab								
LIPID PANEL, STANDARD												
CHOLESTEROL, TOTAL	193		<200 mg/dL									
<b>HDL CHOLESTEROL</b>		<b>47 L</b>	>50 mg/dL									
TRIGLYCERIDES	120		<150 mg/dL									
<b>LDL-CHOLESTEROL</b>		<b>123 H</b>	mg/dL (calc)									
Reference range: <100												
<p>Desirable range &lt;100 mg/dL for primary prevention;            &lt;70 mg/dL for patients with CHD or diabetic patients            with &gt; or = 2 CHD risk factors.</p> <p>LDL-C is now calculated using the Martin-Hopkins            calculation, which is a validated novel method providing            better accuracy than the Friedewald equation in the            estimation of LDL-C.            Martin SS et al. JAMA. 2013;310(19): 2061-2068            (<a href="http://education.QuestDiagnostics.com/faq/FAQ164">http://education.QuestDiagnostics.com/faq/FAQ164</a>)</p>												
CHOL/HDL-C RATIO	4.1		<5.0 (calc)									
<b>NON HDL CHOLESTEROL</b>		<b>146 H</b>	<130 mg/dL (calc)									
<p>For patients with diabetes plus 1 major ASCVD risk            factor, treating to a non-HDL-C goal of &lt;100 mg/dL            (LDL-C of &lt;70 mg/dL) is considered a therapeutic            option.</p>												
HS CRP	1.9		mg/L									
<p>For ages &gt;17 Years:</p> <table border="0"> <tr> <td>hs-CRP mg/L</td> <td>Risk According to AHA/CDC Guidelines</td> </tr> <tr> <td>&lt;1.0</td> <td>Lower relative cardiovascular risk.</td> </tr> <tr> <td>1.0-3.0</td> <td>Average relative cardiovascular risk.</td> </tr> <tr> <td>3.1-10.0</td> <td>Higher relative cardiovascular risk.</td> </tr> </table> <p>Consider retesting in 1 to 2 weeks to            exclude a benign transient elevation            in the baseline CRP value secondary            to infection or inflammation.</p> <p>&gt;10.0      Persistent elevation, upon retesting,            may be associated with infection and            inflammation.</p>					hs-CRP mg/L	Risk According to AHA/CDC Guidelines	<1.0	Lower relative cardiovascular risk.	1.0-3.0	Average relative cardiovascular risk.	3.1-10.0	Higher relative cardiovascular risk.
hs-CRP mg/L	Risk According to AHA/CDC Guidelines											
<1.0	Lower relative cardiovascular risk.											
1.0-3.0	Average relative cardiovascular risk.											
3.1-10.0	Higher relative cardiovascular risk.											
COMPREHENSIVE METABOLIC PANEL												
GLUCOSE	78		65-99 mg/dL									
<p>Fasting reference interval</p>												
UREA NITROGEN (BUN)	13		7-25 mg/dL									
CREATININE	0.78		0.50-1.10 mg/dL									
eGFR NON-AFR. AMERICAN	92		> OR = 60 mL/min/1.73m <sup>2</sup>									
eGFR AFRICAN AMERICAN	106		> OR = 60 mL/min/1.73m <sup>2</sup>									
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)									
SODIUM	135		135-146 mmol/L									
POTASSIUM	4.1		3.5-5.3 mmol/L									
CHLORIDE	104		98-110 mmol/L									

Patient Information	Specimen Information	Client Information
<b>DOB:</b> <b>AGE:</b> Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
CARBON DIOXIDE	23		20-32 mmol/L	
CALCIUM	8.8		8.6-10.2 mg/dL	
PROTEIN, TOTAL	6.6		6.1-8.1 g/dL	
ALBUMIN	4.0		3.6-5.1 g/dL	
GLOBULIN	2.6		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.5		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.4		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	63		33-115 U/L	
AST	14		10-35 U/L	
ALT	9		6-29 U/L	

PERFORMING SITE: